2seventy Bio, Inc. TSVT
Institutional shares held
46.7 Million
116K
calls
7.5K
puts
Total value of holdings
$234M
$578K
calls
$37K
puts
Market Cap
$189M
37,873,600
Shares Out.
Institutional ownership
123.39%
# of Institutions
153
We take great care to ensure that the data presented and summarized in this overview for 2seventy bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TSVT
View all-
Goldman Sachs Group Inc New York, NY4.68MShares$23.4 Million0.0% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA4.25MShares$21.3 Million8.75% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$18.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.97MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$14.1 Million0.0% of portfolio
-
Newtyn Management, LLC New York, NY2.53MShares$12.7 Million2.47% of portfolio
-
Bank Of America Corp Charlotte, NC2.52MShares$12.6 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.5MShares$12.5 Million0.15% of portfolio
-
Man Group PLC London, X02.04MShares$10.2 Million0.03% of portfolio
-
Casdin Capital, LLC New York, NY2MShares$10 Million1.16% of portfolio
Latest Institutional Activity in TSVT
Top Purchases
Top Sells
About TSVT
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at TSVT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2025
|
Sarah Js Glickman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,602
-100.0%
|
-
|
|
May 13
2025
|
Sarah Js Glickman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,050
-43.58%
|
-
|
|
May 13
2025
|
Casdin Capital, LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,000,000
-100.0%
|
$10,000,000
$5.0 P/Share
|
|
May 13
2025
|
Casdin Capital, LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,625
-100.0%
|
$113,125
$5.0 P/Share
|
|
May 13
2025
|
Lin Wei |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,267
-100.0%
|
-
|
|
May 13
2025
|
Lin Wei |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,583
-53.53%
|
-
|
|
May 13
2025
|
Jessica Snow Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,064
-100.0%
|
-
|
|
May 13
2025
|
Jessica Snow Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
247,230
-95.72%
|
-
|
|
May 13
2025
|
Victoria Eatwell Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
43,276
-100.0%
|
-
|
|
May 13
2025
|
Victoria Eatwell Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
401,111
-90.26%
|
-
|
|
May 13
2025
|
Nick Leschly |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
56,233
-100.0%
|
-
|
|
May 13
2025
|
Nick Leschly |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
897,642
-100.0%
|
-
|
|
May 13
2025
|
Nick Leschly |
SELL
Sale (or disposition) back to the issuer
|
Direct |
335,964
-27.23%
|
-
|
|
May 13
2025
|
William D Baird Iii President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
118,209
-100.0%
|
-
|
|
May 13
2025
|
William D Baird Iii President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,002,825
-89.46%
|
-
|
|
May 13
2025
|
Denice Torres |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,510
-100.0%
|
-
|
|
May 13
2025
|
Denice Torres |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,050
-38.18%
|
-
|
|
May 13
2025
|
Charles W. Newton |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,533
-100.0%
|
-
|
|
May 13
2025
|
Charles W. Newton |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,092
-75.54%
|
-
|
|
May 13
2025
|
Marcela V. Maus |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,702
-100.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.48M
Shares
From
9
Insiders
| Grant, award, or other acquisition | 1.48M shares |
|---|
Sell / Disposition
21.7M
Shares
From
25
Insiders
| Sale (or disposition) back to the issuer | 2.06M shares |
|---|---|
| Open market or private sale | 16.4M shares |
| Disposition due to a tender of shares in a change of control transaction | 3.22M shares |